Education
About Us
Working with TipRanks
Follow Us
ImmunityBio (DE:26CA)
FRANKFURT:26CA
26CA Stock Chart & Stats
€7.32
-€0.11(-4.34%)
At close: 4:00 PM EST
€7.32
-€0.11(-4.34%)
Day’s Range― - ―
52-Week Range€1.63 - €7.18
Previous CloseN/A
Volume0.00
Average Volume (3M)9.19K
Market Cap
€7.15B
Enterprise Value€9.68B
Total Cash (Recent Filing)€242.82M
Total Debt (Recent Filing)€40.98M
Price to Earnings (P/E)―
Beta1.11
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding984,965,150
10 Day Avg. Volume5,563
30 Day Avg. Volume9,189
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)-3.65
Price to Sales (P/S)16.08
P/FCF Ratio-5.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.49Price Target Upside15.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Mechanism And Platform PotentialData showing lymphocyte restoration associated with longer survival across tumor types supports ANKTIVA's potential as a combinable immunotherapy backbone beyond bladder cancer.
Commercial TractionRapid uptake after the U.S. launch and rising unit volumes indicate accelerating physician adoption and support revenue growth as ANKTIVA moves toward an established commercial franchise.
Regulatory ApprovalEuropean conditional marketing authorization for ANKTIVA plus BCG establishes broader regulatory validation and meaningfully expands the therapy's commercial runway across multiple jurisdictions.
Bears Say
Clinical Validation RiskQuestions about the durability and functional quality of restored lymphocytes and whether regulators will accept lymphocyte counts as a meaningful endpoint raise the risk that immune restoration may not secure broader label expansions.
Regulatory ObligationsConditional authorization and required post‑marketing commitments create uncertainty around the timing and scope of confirmatory data submissions, posing regulatory and commercial risk.
Reimbursement And Market AccessUncertainty about national reimbursement decisions in Europe could limit initial market penetration and temper commercial forecasts for ANKTIVA.
ImmunityBio News
26CA FAQ
What was ImmunityBio’s price range in the past 12 months?
ImmunityBio lowest stock price was €1.63 and its highest was €7.18 in the past 12 months.
What is ImmunityBio’s market cap?
ImmunityBio’s market cap is €7.15B.
When is ImmunityBio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ImmunityBio’s earnings last quarter?
Currently, no data Available
Is ImmunityBio overvalued?
According to Wall Street analysts ImmunityBio’s price is currently Undervalued.
Does ImmunityBio pay dividends?
ImmunityBio does not currently pay dividends.
What is ImmunityBio’s EPS estimate?
ImmunityBio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmunityBio have?
ImmunityBio has 984,965,150 shares outstanding.
What happened to ImmunityBio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ImmunityBio?
Currently, no hedge funds are holding shares in DE:26CA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImmunityBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€8.49 (15.94% Upside)
€8.49 (15.94% Upside)
Blogger Sentiment
Bullish
DE:26CA Sentiment 83%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 92%
Bearish news 8%
Bearish news 8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
139.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
42.36%
Trailing 12-Months
Company Description
ImmunityBio
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
26CA Stock 12 Month Forecast
Average Price Target
€8.49
▲(15.94% Upside)
Technical Analysis
Catalyst Pharma
―
Immunovant
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Immunocore Holdings
―
Options Prices
Currently, No data available
---